Blepharitis treatment sales will grow through 2036, led by artificial tears at 36.4% of the treatment type segment in 2026, driven by increasing clinical adoption and compliance requirements. The market was valued at USD 453.70 million in 2025 and is expected to be worth USD 792.40 million by 2036.